Form 4: Corcept Director Restructures Share Holdings

Corcept Therapeutics director James N. Wilson reported significant changes in his indirect beneficial ownership of company common stock through estate planning transactions.

Summary

• Director James N. Wilson reported changes in his beneficial ownership of Corcept Therapeutics common stock, effective December 12, 2025.
• Wilson disposed of 400,000 shares of common stock via a gift (Transaction Code G) at a price of $0.00.
• He contributed 200,000 shares of common stock to the James N. Wilson 2025 Grantor Retained Annuity Trust without consideration (Transaction Code J). This trust now indirectly holds 200,000 shares.
• He also contributed another 200,000 shares of common stock to the Pamela D. Wilson 2025 Grantor Retained Annuity Trust without consideration (Transaction Code J). This trust now indirectly holds 200,000 shares.
• These contributions to Grantor Retained Annuity Trusts (GRATs) are for the benefit of himself, Pamela D. Wilson, and their children.
• Following these transactions, Wilson's indirect beneficial ownership includes 1,045,168 shares through the James N. Wilson and Pamela D. Wilson Trust, 200,000 shares through the James N. Wilson 2025 Grantor Retained Annuity Trust, 200,000 shares through the Pamela D. Wilson 2025 Grantor Retained Annuity Trust, and 901,067 shares through James and Pamela Wilson Family Partners.
• Wilson disclaims beneficial ownership of shares held by the trusts and family partners, except to the extent of his pecuniary interest therein.

Sentiment

Score: 6

Explanation: The filing reports insider transactions related to estate planning, which are generally neutral to slightly positive as they indicate long-term planning by a director, rather than a direct sale for cash. The transactions are not directly tied to company performance or operational changes.

Positives

• The transactions are related to estate planning, which often indicates a long-term perspective and commitment to the company by an insider.
• No direct open-market sale of shares for cash by the director is reported, suggesting these are not liquidity-driven dispositions.

Negatives

• The disposition of 400,000 shares via gift, while part of estate planning, represents a transfer out of the director's more direct control, though still within family-related entities.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Industry Context

These types of insider transactions, particularly those involving estate planning vehicles like Grantor Retained Annuity Trusts (GRATs), are common among high-net-worth individuals and corporate insiders. They are typically driven by personal financial planning and tax considerations rather than a direct reflection of the company's immediate operational or financial prospects. Such activities are a standard component of wealth management for executives across various industries.

Comparison to Industry Standards

• Estate planning moves, such as the use of Grantor Retained Annuity Trusts (GRATs), are standard practice for executives and directors in various industries, including biotechnology, to manage wealth and minimize estate taxes.
• These transactions are not indicative of company-specific performance relative to peers like Neurocrine Biosciences (NBIX) or Sage Therapeutics (SAGE), which might also see similar insider estate planning activities.
• The structure of using GRATs is a well-established estate planning tool, commonly employed by high-net-worth individuals across sectors, not unique to Corcept or the biotech industry.

Related Party Transactions

• The transactions involve transfers of shares to trusts for the benefit of the reporting person, his spouse, and children, which are considered related party transactions in the context of beneficial ownership reporting.

Stakeholder Impact

• Shareholders: The transactions represent a reallocation of a director's indirect beneficial ownership, which is generally neutral. It does not directly impact the company's operational performance or outstanding share count.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by these insider ownership restructuring activities.

Key Dates

Recommendation

The filing details routine insider estate planning activities by a director, involving transfers of shares to family trusts. These transactions are not indicative of the company's operational performance or future prospects and do not warrant a change in investment recommendation based solely on this filing. Investors should 'hold' and consider broader company fundamentals and market conditions.

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Transaction, Beneficial Ownership, Estate Planning, Grantor Retained Annuity Trust, GRAT, Director Holdings